24 published briefs
Every entry in Health cleared the same public publication gate: grounded claims, honest provenance, and no draft-state leakage.
THU OCT 29, 2026
Health
This action highlights an escalating trend of state attorneys general intervening in federal drug pricing disputes and holding pharmaceutical companies accountable.
Health
Recent patient fatalities in early-stage clinical trials highlight persistent safety risks and uncertainties surrounding emerging cell and CAR-T therapies for autoimmune conditions.
Health
This development highlights the growing potential of combining targeted cancer drugs without chemotherapy to improve outcomes in aggressive malignancies.
Health
The successful late-stage trial data for intismeran autogene marks a milestone for personalized mRNA cancer vaccines, shifting the field from decades of failure toward new combination therapies for solid tumors.
Health
The release of Nathan Fielder's new film about Elizabeth Holmes highlights ongoing public fascination with the convicted fraudster and raises questions about how media portrayals can obscure historical facts.
Health
Establishing a binding international agreement is critical to prevent a repeat of the widespread social, economic, and health devastation caused by the COVID-19 pandemic.
Health
The case reflects escalating tensions between U.S. and Chinese biotech companies over intellectual property protection and highlights concerns about technology transfer amid growing cross-border investment.
Health
The FDA commissioner leads the agency responsible for regulating drugs, vaccines, and food safety. Overton's nomination signals potential shifts in vaccine policy and pharmaceutical pricing under Trump's second term.